Browsing by Author "Aydin, Mehmet Akif"

Now showing 1 - 4 of 4

B7-H3: a Useful Emerging Diagnostic Marker for Colon Cancer
(Hindawi Ltd, 2022) Bostanci, Ozgur; Sayin, Pinar; Kiziltan, Remzi; Algul, Sermin; Aydin, Mehmet Akif; Kemik, Ozgur
Background. Colon cancer is the second most common malignancy causing the majority of cancer-related deaths. B7-H3 concentrations have drawn major interest as possible diagnostic biomarkers of cancer. The aim of this study was to measure the preoperative serum B7-H3 levels and to determine those that are replaced in colon cancer. Method. We measured preoperative serum B7-H3 concentrations of 90 patients aged 57-69 years diagnosed with colon cancer and 50 age-matched healthy individuals. B7-H3 levels were determined using the sandwich enzyme-linked immunosorbent assay (ELISA). Patients were categorized by stage based on the TNM staging system, and the serum levels of B7-H3 were compared between patients with different TNM stages. Result. No statistically significant difference was found between the patient and control groups in terms of age and gender. Preoperative serum B7-H3 levels were statistically significantly higher in patients with colon cancer than in the healthy group (p < 0.001). Preoperative serum B7-H3 concentration of the stage IV patients was significantly higher than those of the patients with stage I and stage II disease. In addition, higher serum B7-H3 levels were associated with lymph node status and distant metastasis in colon cancer. Conclusion. We showed that B7-H3 is highly expressed in colon cancer and can be used as a candidate diagnostic biomarker and a potential target in colon cancer in future.
Nidogen-2: a New Biomarker in Colon Cancer Patients
(Edizioni Luigi Pozzi, 2022) Kiziltan, Remzi; Cikman, Oztekin; Algul, Sermin; Aydin, Mehmet Akif; Kemik, Ozgur
AIM: In the present study, we followed Nidogen-2 levels and clinicopathological parameters of patients with colon cancer. MATERIAL AND METHODS: Eighty-eight patients (F/M, 43/45; Mean age +/- SD, 57.86 +/- 1.78 years) were included. The results of serum Nidogen-2 levels were shown with respect to stage, gender, age, and metastasis. Nidogen-2 levels in the sera of colon cancer patients and healthy donors were analyzed with ELISA. RESULTS: The expression levels were significantly higher in patients (1010.8 +/- 184.36 pg/mL) than in healthy subjects (51.85 +/- 1.44 pg/mL; p<0.001). Moreover, the Nidogen-2 expression significantly increased in the clinical stages of colon cancer (p<0.01). The Nidogen-2 levels did not vary by patient age or gender. DISCUSSION: Under normal conditions, Nidogen-2 is a basal membrane protein. Nidogen-2 is primarily expressed in the extracellular matrix. Nidogen-2 has been defined as a major means to analyze the molecular pathways involved in cancer development and progression. Besides its important functions, it has been hypothesized that secreted Nidogen-2 may be a diagnostic biomarker for cancer detection. CONLUSION: These findings suggest that increased expression of Nidogen-2 may have great pathological importance in the development of colon cancer and may also show a diagnostic value for colon cancer.
A Novel Marker for Esophageal Cancer: Senescence Marker Protein-30
(Bayrakol Medical Publisher, 2024) Kiziltan, Remzi; Aydin, Mehmet Akif; Algul, Sermin; Kemik, Ozgur
Aim: Esophageal cancer is one of the most common malignancies causing the majority of cancer -related deaths worldwide. The aim of this study was to examine the importance of preoperative Senescence marker protein -30 (SMP30) levels in patients with esophageal cancer. Material and Methods: Medical records of 85 patients who were diagnosed with esophageal cancer were reviewed and compared with those of the control subjects. The tumor marker was measured with Enzyme -linked immunosorbent assay (ELISA). Results: No statistically significant difference was found between the patient and study groups in terms of age and gender. In our study, we found that serum SMP30 levels were significantly lower in esophageal cancer patients than in healthy controls. Discussion: We found that the adhesion of esophageal cancer cells was significantly reflected by preoperative serum levels of the studied marker, indicating the adhesive strength of cancer cells. SMP30 may be a novel strategy for clinical diagnosis of the disease.
Nucleosome Assembly Protein 1-Like 1 (Nap1l1) in Gastric Cancer Patients: a Potential Biomarker With Diagnostic and Prognostic Utility
(Taylor & Francis Ltd, 2024) Gul, Gungor; Aydin, Mehmet Akif; Algul, Sermin; Kiziltan, Remzi; Kemik, Ozgur
Background: The nucleosome assembly protein 1-like 1 (NAP1L1) is suggested to have an oncogenic role in several tumors based on its overexpression. However, its diagnostic and prognostic role in gastric cancer remains unclarified. This study aimed to evaluate the diagnostic and prognostic utility of NAP1L1 in gastric cancer patients. Methods: A total of 85 patients [mean (SD) age: 60.9 (1.6) years, 49.4% were males] with newly-diagnosed gastric cancer and 40 healthy individuals [mean (SD) age: 60.7 (1.7) years, 52.5% were males] were included. Data on patient demographics (age, gender), TNM stages and tumor size, and the serum NAP1L1 levels were recorded. Results: Serum NAP1L1 levels were significantly higher in gastric cancer patients than in control subjects [12 (9.5-13.8) vs. 1.8 (1.5-2.4) ng/mL, p < 0.001]. Also, certain tumor characteristics such as tumor size of >4 vs. <4 cm (p < 0.001), M1 vs. M0 stage (p < 0.001), N2 vs. N0 and N1 stage (p < 0.001), and T4 vs. lower T stage (p < 0.001) were associated with significantly higher serum NAP1L1 levels in gastric cancer patients. Conclusions: Our findings revealed for the first time that serum levels for NAP1L1 were overexpressed in the gastric cancer, as also correlated with the disease progression. NAP1L1 seems to be a potential biomarker for gastric cancer, providing clinically important information on early diagnosis and risk stratification.